pISSN 1226-6051
eISSN 2508-786X
eISSN 2508-786X
Characteristics of included studies
| Study name | Patient | Intervention | Comparator | Registration number | Research period | Patients age |
|---|---|---|---|---|---|---|
| GH | ||||||
| Sode-Carlsen et al. (2010)42) | 46 | GH | Placebo | N/A | 1 year | 16-50 years |
| Festen et al. (2007)41) | 20 | GH (Genotropin) SC 1 mg/m2/day | untreated | N/A | 2 years | 4-9 years |
| Bakker et al. (2015)35) | 47 | GH (Genotropin) 0.035 mg/kg/day | untreated | ISRCTN 49726762 / NTR 628 | 2 years | 6 month-14 years |
| Kuppens et al. (2016 a)40) | 27 | GH (Genotropin) SC 0.67 mg/m2/day | Placebo | NTR1038 | 2 years | 17.2 (1.8) years |
| Myers et al. (2000)30) | 54 | GH (Nutropin) 1 mg/m2/day | untreated | N/A | 2 years | 4-16 years |
| HAQQ et al. (2003)32) | 12 | GH (Genotropin) SC 0.043 mg/kg•d | Placebo SC | N/A | 1 year | 4.5–14.5 years |
| Carrel et al. (1999)18) | 54 | GH (Nutropin) 1 mg/m2/day | untreated | N/A | 1 year | 4-16 years |
| Hoybye et al. (2004)29) | 17 | GH (Genotropin) 0.8 → 1.6 IU (0.26 → 0.53 mg) daily | Placebo | N/A | 18 months | 17-32 years |
| Hauffa et al. (1997)34) | 17 | GH SC 0.15 IU/kg/day | untreated | N/A | 1 year | 3-12 years |
| Hoybye et al. (2003 a)39) | 17 | GH (Genotropin) SC 0.8 → 1.6 IU (0.26 → 0.53 mg) daily | Placebo | N/A | 18 months (Placebo-controlled period: 6 months, Open label GH period: 1 year) | 17-37 years |
| Hoybye et al. (2003 b)31) | 17 | GH (Genotropin) SC 0.8 → 1.6 IU (0.26 → 0.53 mg) daily | Placebo | N/A | 18 months (Placebo-controlled period: 6 months, Open label GH period: 1 year) | 17-32 years |
| De Lind van Wijngaarden et al. (2010)43) | 85 | GH (Genotropin) SC 1.0 mg/m2/day | untreated | N/A | 2 years | 6 month-14 years |
| Carrel et al. (2004)38) | 29 | GH (Genotropin) 1 mg/m2/day | untreated | N/A | 1 year | 4-37 months |
| Lindgren et al. (1998)37) | 29 | GH (Genotropin) SC 0.1 IU/kg/day | untreated | N/A | 1 year | 3-12 years |
| Lindgren et al. (1999)36) | 19 | GH (Genotropin) SC 0.1 - 0.2 IU/kg/day | untreated | N/A | 2 years | 3.8-12.7 years |
| Festen et al. (2008)33) | 91 | GH (Genotropin) SC 1 mg/m2/day | untreated | N/A | 2 years | 3-12 years |
| Non-GH | ||||||
| Anticonvulsunt | ||||||
| Consoli et al. (2019)20) | 62 | Topiramate 50–200 mg/day | Placebo | NCT02810483 | 8 weeks | 12-45 years |
| Cannabinoid receptor CB1 inverse agonist | ||||||
| Motaghedi et al. (2011)24) | 10 | Rimonobant 20 mg | Placebo | N/A | 6 months | 19.5 - 36.3 years |
| Glucagon‐like peptide 1 receptor agonist | ||||||
| Sze et al. (2011)23) | 8 | Exenatide (Byetta) SC 10 μg | Placebo SC (normal saline) | N/A | 4 weeks | 30.0 (2.8) years |
| Oxytocin | ||||||
| Einfeld et al. (2014)27) | 30 | Intranasal oxytocin (11 participants: (13–15 years) 18 IU B.I.D, (16 years and over) 24 IU B.I.D 18 participants: (13–15 years) 32 IU B.I.D, (16 years and over) 40 IU B.I.D) | Placebo | ACTRN12609000982213 | 18 weeks | 12-30 years |
| Kuppens et al. (2016 b)28) | 25 | Intranasal oxytocin (Syntocinon) twice daily (dose range: 24-48 IU/day) | Placebo | NTR4950 | 8 weeks | 6-14 years |
| Damen et al. (2021)19) | 26 | Intranasal oxytocin (Syntocinon) twice daily (dose range: 16-40 IU/day) | Placebo | N/A | 3 months | 3-11 years |
| Selective methionine aminopeptidase 2 inhibitor | ||||||
| McCandless et al. (2017)21) | 107 | Beloranib 1.8 mg or 2.4 mg | Placebo 0.45ml or 0.6ml | NCT02179151 | 1 year (administer 26 weeks) | 12–65 years |
| Serotonin releasing agents | ||||||
| Selikowitz et al. (1990)26) | 15 | Fenfluramine capsule >(5 to 7 years: 10 mg TID, 8 to 15 years: 10 mg → 20 mg TID, Over the age of 15: 20 mg TID → 40 mg TID) | Placebo capsule (lactose) | N/A | 6 weeks | 5.5-27 years |
| Somatostatin receptor agoinist | ||||||
| De Waele et al. (2008)25) | 9 | Octreotide (Sandostatin LAR) IM 30 mg | Placebo IM (saline) | NCT00175305 | 56 weeks | 10.8–18.9 years |
| Unacylated ghrelin analog | ||||||
| Allas et al. (2018)22) | 47 | AZP-531 SC 3 or 4 mg | Placebo | N/A | 2 weeks | 18-40 years |
ACTRN: Australian clinical trials registration number, AZP-531: unacylated ghrelin analog, BID: Bis In Die (=twice a day), GH: growth hormone, IM: intramuscular injection, ISRCTN: International Standard Randomised Controlled Trial Number, IU: International Unit, N/A: not available, NCT: National Clinical Trial (number), NTR: Netherlands Trial Register, SC: subcutaneous injection, TID: Ter In Die (=three times a day), a is indicated as Mean (Standard deviation)